InMed Provides Business Update and Milestones for 2023
10 janv. 2023 07h30 HE
|
InMed Pharmaceuticals Inc.
Complete Phase 2 clinical trial enrollment in Epidermolysis Bullosa in 1Q 2023Progress preclinical research in glaucoma in preparation for human trialsAdvance research using rare cannabinoids in...
Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines
01 nov. 2022 16h05 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced results from a Phase 2 study evaluating the safety and immunogenicity of the company’s adjuvanted...
Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study
24 oct. 2022 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical...
Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3
18 oct. 2022 06h59 HE
|
Synlogic, Inc.
Positive results include clinically meaningful Phe reductions, with a 60% response rate and 42% reduction in plasma Phe among responders across the study population Consistent, positive measures of...
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
26 sept. 2022 09h00 HE
|
Sorrento Therapeutics, Inc.
Phase 2 trial of RTX for OAK pain completed enrollment with last patient (n=120) dosedNo limiting toxicities have been encountered during the trial to date. Patients are now being monitored for...
Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
01 sept. 2022 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian...
View Smart Windows Selected for Phase Two of The Interlock, a Large-Scale, Mixed-Use Project Developed by SJC Ventures in Atlanta
29 août 2022 07h00 HE
|
View, Inc.
ATLANTA and MILPITAS, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- View, Inc. (NASDAQ: VIEW), the leader in smart building technologies, announced its Smart Windows have been selected for phase two of...
Baby Shinja ($BSHINJA) Prepares to Enter Phase 2, Following Certik Audit
19 août 2022 19h15 HE
|
Baby Shinja
BOSTON, MA, Aug. 19, 2022 (GLOBE NEWSWIRE) -- As news begins to trickle out about Ethereum’s long-anticipated Merge upgrade to proof-of-stake, it’s worth pointing out that revolutionary ...
Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
28 juil. 2022 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, July 28, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian...
Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough
18 juil. 2022 08h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, July 18, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian...